GlassScriptPhysician profile
Aakriti Arora
NPI 1528680279
$895.14
in general payments reported to CMS, 2019-2025
10 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $232 · 2024: $414 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.16 |
| Education | $139.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $245.06 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Alexion Pharmaceuticals, INC. | $128.17 | 2023-2024 | Soliris, Ultomiris |
| Jazz Pharmaceuticals INC. | $106.10 | 2023 | Zepzelca |
| Pfizer INC. | $92.68 | 2024-2025 | |
| Seagen INC. | $69.99 | 2023 | |
| Novocure INC. | $68.10 | 2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $53.24 | 2024-2025 | Epkinly, Venclexta |
| Exelixis INC. | $46.86 | 2024 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $44.15 | 2023-2024 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $40.79 | 2023-2024 | Opdivo, Augtyro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aakriti Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.